Phio Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update as It Advances PH-762 Toward Phase 2b Study Initiation
Key Highlights
- ➤PH-762 Phase 2b study expected to begin in first quarter of 2027
- ➤FDA response on proposed PH-762 Phase 2b strategy expected by end-November 2026
- ➤Cash and equivalents $10.6 million at September 30, down from $21.0 million
- ➤Q3 R&D expenses $3.0 million, up 159% year over year
- ➤Q3 net loss $4.2 million versus $2.4 million year earlier
Expert Statements
Robert J. Bitterman, President and Chief Executive Officer of Phio Pharmaceuticals
“We have successfully executed on critical development objectives to advance the PH-762 program toward Phase 2b study initiation”
Robert J. Bitterman, President and Chief Executive Officer of Phio Pharmaceuticals
“Commercial-scale drug substance manufacturing was completed and shipped to our drug product manufacturer in preparation for making clinical trial supply material.”
Robert J. Bitterman, President and Chief Executive Officer of Phio Pharmaceuticals
“We have submitted detailed information to FDA providing final analysis of our Phase 1b clinical trial and the fundamentals of our intended upcoming Phase 2b study.”
PH-762 Program Accomplishes Major Development Milestones Including Completion of Commercial-Scale cGMP Manufacturing, Treatment in Long-Term Toxicology Study, and Submission of Key Regulatory Documents to FDA
King of Prussia, Pennsylvania--(Newsfile Corp. - November 5, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biopharmaceutical company developing therapeutic products based on its proprietary INTASYL(®) gene-silencing technology to eliminate cancer, today reported financial results for the quarter ended September 30, 2026, and provided a business update.
Get started
Create a free account to read the full story.